Vium improves the speed and reproducibility of preclinical research to better predict how drugs perform in humans. Vium was acquired by Recursion Pharmaceuticals in 2020.
Vium empowers biomedical investigators with technology that accelerates the preclinical drug discovery and development pipeline. Researchers can design, run, and analyze experiments that rapidly surface insights and high volumes of quality data. The result is that better therapies get moved more quickly through to patients who need them.
- Joe Betts-Lacroix
- Tim Robertson
- Even while Vium employees are Sheltering In Place, we continue to have team fun. If you are looking for something… https://t.co/hRYWOsVRic
- Congratulations to Laura for being one of the top 50 Healthcare Technology CEOs for 2020!! https://t.co/xhDgnCl6UQ https://t.co/G0EIgyrX4l
- Vium is hiring! Are you a talented and driven Software Engineer who wants to make a difference in drug discovery an… https://t.co/jRcASMy4Ih